Dear investigator,

Virovek (http://www.virovek.com/), a contract research organization specializing in recombinant AAV production acts as the Viral Vector Core for Target ALS Foundation. Virovek offers comprehensive gene construct design, synthesis, and cloning of transgene plasmids.

Virovek offers Target ALS Foundation investigators a special price of $2,500 for each custom AAV production. There are additional costs related to cloning services ($695 and up, depending on requirements) and shipping. The AAV is produced at a titer of $1x10^{13}$vg/mL and concentrated to our **recommended titer** of $1x10^{14}$vg/mL, which is shipped in two 100µL aliquots. Please see attached slide for AAV core process. Target ALS Foundation also provides detailed protocols for use of AAV vectors to target CNS and muscle in neonatal rodents.

For each Target ALS-funded team in an academic or non-profit institution Target ALS will cover the costs of AAV production (but not cloning or shipping) for two (2) custom AAV projects. All proposals for Target ALS funding will be evaluated by Target ALS central administration. Investigators should send a 1-2 page project description to Target ALS that includes a specific statement of relevance to the current Target ALS project and preliminary data (including validation of the shRNA - >70% knockdown - or cDNA – clear evidence for expression of full-length mRNA or protein - to be cloned). To avoid duplication, the cover letter from the Target ALS-funded PI should clearly state that these are the projects proposed from her/his lab for Target ALS funding. Other requests can be sent directly to Virovek.

Target ALS has tested AAV6-GFP and AAV9-GFP from Virovek. Both stably transduced motor neurons throughout the spinal cord with high efficiency (~70%) following a single i.c.v. injection into neonatal mice. To allow for sufficient training using the protocol, Virovek is offering each new customer two 100-µL aliquots of high-titer AAV-GFP control vectors for free (shipping costs included). Please report to Manish Raisinghani (President, Target ALS Foundation) at manish.raisinghani@TargetALS.org any problems you encounter when using the Viral Vector Core.

Best regards,

Chris Henderson
Chief Advisor, Target ALS Foundation